Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ACLY | P53396 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10919386 | 0.94 | IDO1 (0.50) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL9591964 | 0.92 | ACLY (0.49) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL398220 | 0.87 | IDO1 (0.56) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL16956209 | 0.83 | TP53 (0.41) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL11621292 | 0.82 | IDO1 (0.65) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL7988972 | 0.81 | IDO1 (0.54) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL1808181 | 0.79 | IDO1 (0.57) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL895036 | 0.79 | IDO1 (0.52) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL11279910 | 0.79 | IDO1 (0.52) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL585759 | 0.79 | IDO1 (0.52) | IDO1CYP1A2CYP3A4CYP2C9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230018615-A1 | STEROIDS AND METHODS OF MANUFACTURE | TRUSTEES OF DARTMOUTH COLLEGE | 2023-01-19 | — | — | US | disclosed |
| EP-3153023-B1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-16 | — | — | EP | disclosed |
| US-20210253566-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. | 2021-08-19 | — | — | US | disclosed |
| CN-112961149-A | Cytochrome P450 inhibitors and uses thereof | 安吉恩生物医药公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20210171515-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. | 2021-06-10 | — | — | US | disclosed |
| EP-3180335-B1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-107074841-B | Cytochrome P450 inhibitors and uses thereof | 安吉恩生物医药公司 | 2021-03-26 | — | — | CN | disclosed |
| EP-2976086-B1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-20200199171-A1 | NOVEL STEROIDS AND METHODS OF MANUFACTURE | TRUSTEES OF DARTMOUTH COLLEGE | 2020-06-25 | — | — | US | disclosed |
| US-10556893-B2 | Cytochrome P450 inhibitors and uses thereof | ANGION BIOMEDICA CORP. (US) | 2020-02-11 | — | — | US | disclosed |
| EP-0811614-A1 | Benzyloxy substituted aromatics and their use as fungicides and insecticides | ROHM AND HAAS COMPANY (US) | 1997-12-10 | — | — | EP | disclosed |
| US-5635494-A | CONTROLLING PHYTOPATHOGENIC FUNGI, INSECTS | ROHM AND HAAS COMPANY (US) | 1997-06-03 | — | — | US | disclosed |
| EP-0738716-A2 | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides | ROHM AND HAAS COMPANY (US) | 1996-10-23 | — | — | EP | disclosed |
| US-5466821-A | Triazole ring containing fungicides, intermediates | ZENECA LIMITED (GB) | 1995-11-14 | — | — | US | disclosed |
| US-5449785-A | Fungicides with triazole groups | HOFFMANN-LA ROCHE INC. (US) | 1995-09-12 | — | — | US | disclosed |
| US-5395942-A | Fungicides for plants | ZENECA LIMITED (GB) | 1995-03-07 | — | — | US | disclosed |
| EP-0636120-A1 | EPOXIDATION PROCESS OF CARBONYL COMPOUNDS USING SULPHONIUM OR SULPHOXONIUM YLIDES AND INTERMEDIATES | ZENECA LIMITED (GB) | 1995-02-01 | — | — | EP | disclosed |
| EP-0524439-A1 | Novel cyclohexane and tetrahydropyran derivatives and antifungal compositions containing these derivatives | F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) | 1993-01-27 | — | — | EP | disclosed |
| WO-1992014703-A1 | EPOXIDATION PROCESS OF CARBONYL COMPOUNDS USING SULPHONIUM OR SULPHOXONIUM YLIDES AND INTERMEDIATES | ZENECA LIMITED (GB) | 1992-09-03 | — | — | WO | disclosed |
| US-5004494-A | Fungicides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171515-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | CYP7A1, CYP2E1, CYP11B1 | IDO1 398/4885CYP1A2 4/4885CYP3A4 35/4885 |
| US-20230018615-A1 | STEROIDS AND METHODS OF MANUFACTURE | HSD17B7, HSD11B1, HSD11B2 | IDO1 2268/4885CYP1A2 133/4885CYP3A4 82/4885 |
| US-20210253566-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | CYP7A1, CYP2E1, CYP1A2 | IDO1 293/4885CYP1A2 3/4885CYP3A4 36/4885 |
| US-20200199171-A1 | NOVEL STEROIDS AND METHODS OF MANUFACTURE | CYP21A2, CYP17A1, CYP11B1 | IDO1 2315/4885CYP1A2 103/4885CYP3A4 130/4885 |
| US-10556893-B2 | Cytochrome P450 inhibitors and uses thereof | CYP7A1, CYP2E1, CYP1A2 | IDO1 293/4885CYP1A2 3/4885CYP3A4 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.